Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Nozia, Ibset, Rsgram
Synonyms :
ramosetron
Class :
Gastrointestinal agent, Antiemetic, Serotonin 5-HT3 receptor antagonist
Brand Name :
Nozia, Ibset, Rsgram
Synonyms :
ramosetron
Class :
Gastrointestinal agent, Antiemetic, Serotonin 5-HT3 receptor antagonist
Dosage forms& StrengthsÂ
TabletÂ
2.5 mcgÂ
5 mcgÂ
100 mcgÂ
Injectable SolutionÂ
300 mcg/2 mLÂ
Chemotherapy Induced Vomiting And NauseaÂ
It is indicated for the treatment of vomiting and nausea associated with cancer treatment
The recommended usual dose via oral administration is 100 mcg one time daily
The recommended usual dose via intravenous administration is 300 mcg one time daily, which can be increased to an additional 300 mcg when required, and the maximum should not exceed 600 mcg
Dose Adjustments
Limited data is available
Irritable Bowel Syndrome (IBS)Â
It is indicated for the treatment of IBS
The usual recommended dose via oral administration is 5 mcg one time a day, which should not exceed 10 mcg a day
Dose Adjustments
Limited data is available
Safety and efficacy studies are not seen in pediatricsÂ
Refer to the adult dosingÂ
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the constipating effect of opioid drugs
ramosetron: they may increase the constipating effect of opioid drugs
ramosetron: they may increase the constipating effect of opioid drugs
ramosetron: they may increase the constipating effect of opioid drugs
ramosetron: they may enhance the serum concentration of CYP1A2 Inhibitors
ramosetron: they may enhance the serum concentration of CYP1A2 Inhibitors
ramosetron: they may enhance the serum concentration of CYP1A2 Inhibitors
ramosetron: they may enhance the serum concentration of CYP1A2 Inhibitors
ramosetron: they may enhance the serum concentration of CYP1A2 Inhibitors
ramosetron: they may increase the constipating effect of mu-opioid receptor agonists
ramosetron: they may increase the constipating effect of mu-opioid receptor agonists
ramosetron: they may decrease the therapeutic effect of antipsychotics
ramosetron: they may decrease the therapeutic effect of antipsychotics
ramosetron: they may decrease the therapeutic effect of antipsychotics
ramosetron: they may decrease the therapeutic effect of antipsychotics
ramosetron: they may decrease the therapeutic effect of antipsychotics
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the sedative effect of CNS stimulants
ramosetron: they may increase the sedative effect of CNS stimulants
ramosetron: they may increase the sedative effect of CNS stimulants
ramosetron: they may increase the sedative effect of CNS stimulants
ramosetron: they may increase the sedative effect of CNS stimulants
ramosetron: they may enhance the serum concentration of CYP2D6 Inhibitors
ramosetron: they may enhance the serum concentration of CYP2D6 Inhibitors
ramosetron: they may enhance the serum concentration of CYP2D6 Inhibitors
ramosetron: they may enhance the serum concentration of CYP2D6 Inhibitors
ramosetron: they may enhance the serum concentration of CYP2D6 Inhibitors
ramosetron: they may increase the antiplatelet effect of Agents with antiplatelet properties
ramosetron: they may increase the antiplatelet effect of Agents with antiplatelet properties
ramosetron: they may increase the antiplatelet effect of Agents with antiplatelet properties
ramosetron: they may increase the antiplatelet effect of Agents with antiplatelet properties
ramosetron: they may increase the antiplatelet effect of Agents with antiplatelet properties
the combination of ramosetron with atracurium may increase the chances of cns depression
ramosetron may enhance the central nervous system depressant (cns depressant) activities of azelastine
may increase the CNS depressant effect
may increase the constipating effect of anticholinergic agents
may increase the constipating effect of anticholinergic agents
may increase the constipating effect of Anticholinergic Agents
the combination of atropine and ramosetron may increase the chances of constipation
when combined with axitinib, the metabolism of ramosetron may be reduced
the metabolism of ramosetron may be reduced when combined with azathioprine
the central nervous system depressant (cns depressant) activities of ramosetron may be increased by baclofen
when combined with belinostat, the metabolism of ramosetron may be increased
when combined with bendamustine, the metabolism of ramosetron may be reduced
Actions and spectrum:Â
Ramosetron prevents nausea and vomiting during chemotherapy because it blocks serotonin, a chemical produced in the brain which can trigger these symptoms after surgery and chemotherapy.Â
Adverse reactionsÂ
Hepatic dysfunctionÂ
RashÂ
Numbness of tongueÂ
Raised BUNÂ
Hot flushesÂ
DiarrheaÂ
HeadacheÂ
ItchingÂ
HiccupÂ
HeatÂ
RednessÂ
Black box warningÂ
Keep away from the reach of childrenÂ
Contraindications/CautionÂ
ContraindicationsÂ
HypersensitivityÂ
CautionsÂ
Renal impairmentÂ
ConstipationÂ
Hepatic impairmentÂ
Drug interactionsÂ
GeriatricsÂ
Pregnancy Â
BreastfeedingÂ
Pregnancy & breastfeeding:Â
Pregnancy consideration:Â
Safety and efficacy studies about the use of the drug in pregnancy is not availableÂ
Breastfeeding warnings:Â
Data about the excretion of the drug into breast milk is not knownÂ
Pregnancy category:Â
Pharmacology:Â
Ramosetron is a selective antagonist of 5-HT3 which is indicated as an anti-emetic agent.Â
Pharmacodynamics:Â
This drug belongs to a class of drugs that inhibit the 5-HT3 receptors. It prevents the binding of serotonin to 5-HT3 receptors in the GU mucosa’s afferent vagal nerve terminals and acts as an antiemetic agent. The time for onset of the drug’s action has no scientific reason but the drug remains in the system for 48 hours after administration.Â
Pharmacokinetics:Â
Metabolism:Â
The drug is known to undergo metabolism via CYP2D6 and CYP1A2.Â
Excretion:Â
It is known to be excreted through urine.Â
Half-life: 5 hoursÂ
Administration:Â
It is should be taken orally and also via intravenous administration one time a day with or without meals.Â
Patient information leafletÂ
Generic Name: ramosetronÂ
Why do we use ramosetron?Â
Ramosetron is a 5-HT3 receptor antagonist of serotonin used to treat nausea and vomiting caused by chemotherapy and radiation. It also helps with managing nausea and vomiting during any stage of cancer treatment. Postoperatively it’s used for preventing PONV (Post Operative Nausea & Vomiting) after surgeries.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
